Test assesses all inherited Parkinson's disease genes
Answers from the Lab
Genetic mutations cause up to 15% of cases of Parkinson's disease. In this test-specific episode of the "Answers From the Lab" podcast, Zhiyv (Neal) Niu, Ph.D., and Rodolfo Savica, M.D., Ph.D., explain why Mayo Clinic Laboratories' gene panel outperforms other commercially available tests for inherited Parkinson's disease.
"Our test is the most comprehensive available in the market. It looks at 94 genes — more than three times the number analyzed in other commercially available tests," Dr. Savica says.
The novel panel identifies not only mutations known to cause Parkinson's disease but also mutations that increase the risk of developing it.
"This test can be incredibly helpful for patients who have a family history of Parkinson's disease and also patients with earlier onset of disease," Dr. Savica says. "We now have a bigger piece of the puzzle — something that can really allow an individualized approach towards Parkinson's disease."
Listen to learn more about Mayo Clinic Laboratories' inherited Parkinson's disease gene panel.
Note: Podcasts will not play back on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.
A previous bone marrow transplant from an allogenic donor will interfere with testing. Call 800-533-1710 for instructions for testing patients who have received a bone marrow transplant.
Specimen Type: Whole blood
Container/Tube: Lavender top (EDTA) or yellow top (ACD)
Acceptable: Any anticoagulant
Specimen Volume: 3 mL
Specimen Stability Information: Ambient (preferred)/Refrigerated
Anne Tebo, Ph.D., explains how Mayo Clinic Laboratories' new serum tests help overcome the challenges of diagnosing primary biliary cholangitis, or PBC. Test results can guide clinical care for patients with this life-threatening autoimmune liver disease.
David Murray, M.D., Ph.D., explains how Mayo Clinic Laboratories' MASS-FIX Quantitation assay provides next-generation screening for M-proteins, which are associated with multiple myeloma and other diseases. The assay better quantitates the blood proteins, for improved patient care and simpler test ordering.
Joshua Bornhorst, Ph.D., explains how Mayo Clinic Laboratories' unique assay identifies pregnant women at risk of developing preeclampsia with severe features. Test results can guide clinical management, to safeguard maternal and neonatal health.